NSNan Sethakorn

Nan Sethakorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nan Sethakorn has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data 1 from Longitudinal Phenotyping of Circulating Tumor Cells Using a Scalable Deep Learning Framework

    by Matthew L. Bootsma, Marina N. Sharifi, Jamie M. Sperger, Jennifer L. Schehr, William M. Stump, Hamza Bakhtiar, Matthew Mannino, Viridiana Carreno, Alex H. Chang, Charlotte Stahlfeld, et al.

    All supplementary Figures and tables.

  • Longitudinal Phenotyping of Circulating Tumor Cells Using a Scalable Deep Learning Framework

    by Matthew L. Bootsma, Marina N. Sharifi, Jamie M. Sperger, Jennifer L. Schehr, William M. Stump, Hamza Bakhtiar, Matthew Mannino, Viridiana Carreno, Alex H. Chang, Charlotte Stahlfeld, et al.

    Purpose: Circulating tumor cells (CTC) provide a minimally invasive window into metastatic disease and treatment response, but their clinical utility has been constrained by manual, subjective, low-throughput identification in multichannel fluorescence microscopy data. Experimental Design: To address this limitation, we developed and clinically validated the System for Enhanced Evaluation of Tumor Cells (SEE-TC), a deep learning approach for scalable, reproducible phenotyping of individual circulating cells. SEE-TC was developed and evaluated on more than 8.5 million cells from 3,386 blood samples spanning six cancer types, enabling generalization across heterogeneous imaging conditions, staining panels, and acquisition platforms. Results: SEE-TC achieved single-cell segmentation accuracy on par with humans, learned biologically relevant latent cellular representations that correlate with established morphologic and immunofluorescent biomarkers, and reliably distinguished CTCs from background populations without reliance on arbitrary thresholds. When applied longitudinally, SEE-TC provides a quantitative, patient-level readout of CTC burden over time, which was significantly associated with worse overall survival across multiple cancer types. Conclusions: To our knowledge, this is the first fully automated artificial intelligence approach to single-cell segmentation and CTC phenotyping. By transforming CTC analysis from a human-dependent task into a scalable and reproducible digital assay, SEE-TC enables high-fidelity longitudinal monitoring of tumor burden and supports broader clinical deployment of CTC-based liquid biopsies in precision oncology. It is currently being deployed to identify CTCs and quantify target expression for both prognostic and predictive biomarker evaluation in multiple prospective clinical trials on a commercial platform.


  • Open Access

    Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response

    by Cristina Sánchez-De-Diego, Ravi Chandra Yada, Nan Sethakorn, Peter G. Geiger, Adeline B. Ding, Erika Heninger, Fauzan Ahmed, María Virumbrales-Muñoz, Nikolett Lupsa, Emmett Bartels, et al.

    Bone is the most common site of prostate cancer metastasis, leading to significant morbidity, treatment resistance, and mortality. A major challenge in understanding treatment response is the complex, bone metastatic niche. Here, we report the first patient-specific microphysiological system (MPS) to incorporate six primary human stromal cell types found in the metastatic bone niche (mesenchymal stem cells, adipocytes, osteoblasts, osteoclasts, fibroblasts, and macrophages), alongside an endothelial microvessel, and prostate tumor epithelial spheroids in an optimized media that supports their viability and phenotype. We tested two standard of care drugs, darolutamide and docetaxel, in addition to sacituzumab govitecan (SG), currently in clinical trials for prostate cancer, demonstrating that the MPS accurately replicates androgen response sensitivity and captures stromal microenvironment-mediated resistance. This advanced MPS provides a robust platform for investigating the biological mechanisms of treatment response and for identification and testing of therapeutics to advance patient-specific MPS towards personalized clinical-decision making.


  • Open Access

    A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer

    by Wade T. Iams, Meridith L. Balbach, Sharon Phillips, Adrian Sacher, Christine Bestvina, Vamsidhar Velcheti, Xiao Wang, Melina E. Marmarelis, Nan Sethakorn, Ticiana Leal, et al.


  • Open Access

    A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

    by Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, et al.

    Background. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer. Methods. We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify the limit of quantification (LOQ) in cell lines, synthetic cDNA, and patient samples. We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor signaling inhibitors (ARSIs). We assessed a NEPC liquid biomarker via the presence of neuroendocrine markers and the absence of androgen receptor (AR) target genes. Results. Using the analytical validation LOQ, liquid biomarker NEPC detection in the longitudinal cohort had a per-sample sensitivity of 51.35% and a specificity of 91.14%. However, when we incorporated the serial information from multiple liquid biopsies per patient, a unique aspect of this study, the per-patient predictions were 100% accurate, with a receiver-operating-curve (ROC) AUC of 1. In the adenocarcinoma ARSI trials, the presence of neuroendocrine markers, even while AR target gene expression was retained, was a strong negative prognostic factor. Conclusion. Our analytically validated CTC biomarker can detect NEPC with high diagnostic accuracy when leveraging serial samples that are only feasible using liquid biopsies. Patients with expression of NE genes while retaining AR-target gene expression may indicate the transition to neuroendocrine differentiation, with clinical characteristics consistent with this phenotype. Funding. NIH (DP2 OD030734, 1UH2CA260389, R01CA247479, and P30 CA014520), Department of Defense (PC190039 and PC200334), and Prostate Cancer Foundation (Movember Foundation — PCF Challenge Award).


  • Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma

    by Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, et al.

    PURPOSE: Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach. METHODS: We collected 457 longitudinal liquid biopsies from 104 patients with mRCC enrolled in one of two studies, either a prospective cohort or a phase II multicenter adaptive immunotherapy trial. Using a novel CTC capture and automated microscopy platform, we profiled CTC enumeration and expression of HLA I and programmed cell death-ligand 1 (PD-L1). Given their diametric immunological roles, we focused on the HLA I to PD-L1 ratio (HP ratio). RESULTS: Patients with radiographic responses showed significantly lower CTC abundances throughout treatment. Furthermore, patients whose CTC enumeration trajectory was in the highest quartile (> 0.12 CTCs/mL annually) had shorter overall survival (median 17.0 months v 21.1 months, P < .001). Throughout treatment, the HP ratio decreased in patients receiving immunotherapy but not in patients receiving tyrosine kinase inhibitors. Patients with an HP ratio trajectory in the highest quartile (≥ 0.0012 annually) displayed significantly shorter overall survival (median 18.4 months v 21.2 months, P = .003). CONCLUSION: In the first large longitudinal CTC study in mRCC to date to our knowledge, we identified the prognostic importance of CTC enumeration and the change over time of both CTC enumeration and the HP ratio. These insights into changes in both tumor burden and the molecular profile of tumor cells in response to different treatments provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.


  • Open Access

    Abstract 207: MET inhibition enhances the effect of radiation in MET mutated non-small cell lung cancer brain metastasis patient derived xenografts

    by Kwangok P. Nickel, Shrey Ramesh, Saahil Javeri, Nitin Somasundaram, Nan Sethakorn, Randall J. Kimple, Andrew M. Baschnagel

    Objective: The MET receptor is mutated in 3-4% and amplified in 1-6% of patients with non-small cell lung cancer. The most common MET mutation is in exon 14, which results in deletion of the intracellular juxtamembrane domain of the receptor, leading to enhanced signaling. Mutation at Asp-1000 in the juxtamembrane region has also been reported and can lead to inhibition of apoptosis and cell proliferation. MET is involved in multiple pathways associated with radiation response. Therefore, we investigated the effects of inhibiting MET in combination with radiation in two preclinical non-small cell lung cancer (NSCLC) brain metastasis patient derived xenograft (PDX) models. Methods: Surgically obtained tissue was implanted subcutaneously into immunodeficient mice. Histology and DNA loci were compared between original tumor and PDX. DNA sequencing was performed on tumors for mutation analysis. In vivo growth responses to the MET inhibitor capmatinib or savolitinib with and without radiation were assessed. Radiation was delivered in 10 daily fractions of 2 Gy. Drug was administered by oral gavage daily 1 hour prior to radiation at a dose of 2.5 mg/kg for savaolitnib or 20 mg/kg for capmatinib for 10 days. Immunohistochemistry (IHC) was performed to evaluate MET signaling and proliferation. Results: PDXs were successfully established from two patients with MET mutated NSCLC brain metastases: a lung adenocarcinoma with a MET exon 14 skipping mutation and a lung sarcomatoid carcinoma with adenocarcinoma component with an Asp-1000 frameshift mutation. Morphologically, strong retention of cytoarchitectural features was observed between original patient tumors and PDXs. Short tandem repeat analysis confirmed 100% matching of alleles between patient tumors and PDXs. DNA sequencing confirmed METex14 and MET Asp-1000 frameshift mutation. In the METex14 PDX, savolitinib alone significantly inhibited tumor growth with a growth inhibition value of 46% (pCitation Format: Kwangok P. Nickel, Shrey Ramesh, Saahil Javeri, Nitin Somasundaram, Nan Sethakorn, Randall J. Kimple, Andrew M. Baschnagel. MET inhibition enhances the effect of radiation in MET mutated non-small cell lung cancer brain metastasis patient derived xenografts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 207.

  • Open Access

    Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment

    by Nan Sethakorn, Erika Heninger, Cristina Sánchez-De-Diego, Adeline B. Ding, Ravi Chandra Yada, Sheena C. Kerr, David Kosoff, David J. Beebe, Joshua M. Lang

    Bone metastases represent a lethal condition that frequently occurs in solid tumors such as prostate, breast, lung, and renal cell carcinomas, and increase the risk of skeletal-related events (SREs) including pain, pathologic fractures, and spinal cord compression. This unique metastatic niche consists of a multicellular complex that cancer cells co-opt to engender bone remodeling, immune suppression, and stromal-mediated therapeutic resistance. This review comprehensively discusses clinical challenges of bone metastases, novel preclinical models of the bone and bone marrow microenviroment, and crucial signaling pathways active in bone homeostasis and metastatic niche. These studies establish the context to summarize the current state of investigational agents targeting BM, and approaches to improve BM-targeting therapies. Finally, we discuss opportunities to advance research in bone and bone marrow microenvironments by increasing complexity of humanized preclinical models and fostering interdisciplinary collaborations to translational research in this challenging metastatic niche.


  • Spectrum of genomic alterations in FGFR 3 : current appraisal of the potential role of FGFR 3 in advanced urothelial carcinoma

    by Nan Sethakorn, Peter H. O'DOnnell

    Molecular analysis has identified subsets of urothelial carcinoma ( UC ) expressing distinct genetic signatures. Genomic alterations in the oncogenic fibroblast growth factor receptor 3 ( FGFR 3 ) pathway are among the most well described in UC and have led to extensive and ongoing investigation of FGFR 3‐targeted therapies in this disease, although no new drugs have yet been approved. Given the unmet need for effective treatments in advanced and metastatic UC , a better understanding of the known molecular alterations of FGFR 3 and of the previous and ongoing clinical investigations of this promising target in UC deserves attention. The objective of the present review is to describe the landscape of alterations and biology of FGFR 3 in UC , comprehensively summarize the current state of UC clinical trials of FGFR 3 inhibitors, and discuss future therapeutic applications. Using the Pubmed and Clinicaltrials.gov databases, articles describing the spectrum and biological activity of FGFR 3 genomic alterations and trials of FGFR 3 inhibitors in UC were identified. Search terms included ‘ FGFR 3 genomic alterations’ and ‘urothelial cancer’ or ‘bladder cancer’. Genomic alterations, including translocations and activating mutations, are increasingly described in advanced and metastatic UC . The majority of clinical trials have been performed in unselected populations; however, recent studies have reported encouraging preliminary data. We argue that routine use of molecular genomic tumour analysis in UC may inform selection of patients for appropriate trials and we further investigate the potential of FGFR 3 as a meaningful clinical target for this difficult disease.